Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes
Open Access
- 23 December 2019
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 3 (24), 4228-4237
- https://doi.org/10.1182/bloodadvances.2019000925
Abstract
Patients with therapy-related acute lymphoblastic leukemia (t-ALL) represent a small subset of acute lymphoblastic leukemia (ALL) patients who received genotoxic therapy (ie, chemotherapy or radiation) for a prior malignancy. These patients should be distinguished from patients with de novo ALL (dn-ALL) and ALL patients who have a history of prior malignancy but have not received cytotoxic therapies in the past (acute lymphoblastic leukemia with prior malignancy [pm-ALL]). We report a retrospective multi-institutional study of patients with t-ALL (n = 116), dn-ALL (n = 100), and pm-ALL (n = 20) to investigate the impact of prior cytotoxic therapies on clinical outcomes. Compared with patients with pm-ALL, t-ALL patients had a significantly shorter interval between the first malignancy and ALL diagnosis and a higher frequency of poor-risk cytogenetic features, including KMT2A rearrangements and myelodysplastic syndrome-like abnormalities (eg, monosomal karyotype). We observed a variety of mutations among t-ALL patients, with the majority of patients exhibiting mutations that were more common with myeloid malignancies (eg, DNMT3A, RUNX1, ASXL1), whereas others had ALL-type mutations (eg, CDKN2A, IKZF1). Median overall survival was significantly shorter in the t-ALL cohort compared with patients with dn-ALL or pm-ALL. Patients who were eligible for hematopoietic cell transplantation had improved long-term survival. Collectively, our results support t-ALL as a distinct entity based on its biologic and clinical features.Keywords
This publication has 26 references indexed in Scilit:
- Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancyLeukemia & Lymphoma, 2015
- Secondary acute lymphoblastic leukaemia is constitutional and probably not related to prior therapyBritish Journal of Haematology, 2015
- Therapy-related ALL: cytogenetic features and hematopoietic cell transplantation outcomeBone Marrow Transplantation, 2015
- Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemiaNature, 2014
- Characterization and prognostic features of secondary acute myeloid leukemia in a population‐based setting: A report from the Swedish Acute Leukemia RegistryAmerican Journal of Hematology, 2014
- Survival of Adults with Acute Lymphoblastic Leukemia in Germany and the United StatesPLOS ONE, 2014
- Therapy‐related acute lymphoblastic leukemia is more frequent than previously recognized and has a poor prognosisCancer, 2011
- Therapy-Related Myeloid LeukemiaSeminars in Oncology, 2008
- Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AMLLeukemia, 2003
- Polymorphism in glutathione S -transferase P1 is associated with susceptibility to chemotherapy-induced leukemiaProceedings of the National Academy of Sciences, 2001